Onkologie. 2011:5(1):23-27

Anthracyclines in treating metastatic breast cancer

Katarína Petráková
Masarykův onkologický ústav, Brno

Metastatic breast cancer is an incurable disease. It is a chemosensitive disease in which chemotherapy significantly prolongs the survival

of patients. Anthracyclines are among the most effective cytostatic drugs in the treatment for breast cancer. The major limitation of treatment

is the cardiotoxicity of anthracyclines which increases after the cumulative dose is reached. The treatment of patients pretreated with

adjuvant anthracyclines is thus problematic. Liposomal doxorubicin (Myocet) which has been shown to have equal efficacy to conventional

anthracyclines, but lower cardiotoxicity in first-line treatment for metastatic disease in clinical trials seems to be a good alternative.

Keywords: anthracyclines, cardiotoxicity, liposomal doxorubicin

Published: February 25, 2011  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Petráková K. Anthracyclines in treating metastatic breast cancer. Onkologie. 2011;5(1):23-27.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Mauri D, Polyzos NP, Salanti G, et al. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in advanced breast cancer. J Natl Cancer Inst. 2008; 100(24): 1780-1791. Go to original source... Go to PubMed...
    2. Early Breast Cancer Trialits´Collaborative Group. Effect of chemotherapy and hormonal therapy for early breast cancer on reccurence and 15-year survival: an overview of the randomised trials.Lancet 2005; 365(9472): 1687-1717. Go to original source... Go to PubMed...
    3. Morabito A, Piccirillo MC, Monaco K, et al. First-line chemotherapy for HER-2 negative metastatic breast cancer patients who received anthracyclines as adjuvant treatment. Oncologist 2007; 12: 1288-1298. Go to original source... Go to PubMed...
    4. Jassem J, Pienkowski T, Pluzanska A, et al. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: Final results of a randomized phase III multicenter trial. J Clin Oncol 2001; 19: 1707-1715. Go to original source... Go to PubMed...
    5. Bontenbal M, Creemers GJ, Braun HJ, et al. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: Results of a Dutch community setting trial for the Clinical Trial Group of the Comprehensive Cancer Centre. J Clin Oncol 2005; 23: 7081-7088. Go to original source... Go to PubMed...
    6. Piccart-Gebhart MJ, Burzykowski T, et al. Taxanes Alone or in Combination With Anthracyclines As First-Line Therapy of Patients With Metastatic Breast Cancer. J Clin Oncol 2008; 28: 1980-1986. Go to original source... Go to PubMed...
    7. Conte PF, Guarneri V, Bruzzi P, et al. Concomitant versus sequential administration of epirubicin and paclitaxel as firstline therapy in metastatic breast carcinoma: resultes for the Gruppo Omcologico Nord Ovest randomized trial. Cancer. 2004; 101(4): 704-712. Go to original source... Go to PubMed...
    8. Alba E, Martin M, Ramos M, et al. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study. J Clin Oncol. 2004; 22(13): 2587-2593. Go to original source... Go to PubMed...
    9. Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717. Go to original source... Go to PubMed...
    10. Cortes EP, Lutman G, Wanka J, et al. Adriamycin (NSC123127) cardiotoxicity: A clinicopathological correlation. Cancer Chemother Rep 1975; 6: 215-225.
    11. Launchbury AP, Habboubi N. Epirubicin and doxorubicin: a comparison of their characteristics, therapeutic activity cardiotoxicity. Cancer Treat Rev 1993; 19: 197-228. Go to original source... Go to PubMed...
    12. Kanter PM, Klaich G, Bullard G, et al. Preclinical toxicology study of liposome encapsulated doxorubicin (TLC D-99) given intraperitoneally to dogs. In Vivo 1994; 8: 975-982. Go to PubMed...
    13. Batist G, Ramakrishnan G, Rao CS, et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19(1): 1444-1454. Go to original source... Go to PubMed...
    14. Harris L, Batist G, Belt R, et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94(1): 25-36, 1527-1534. Go to original source... Go to PubMed...
    15. Chan S, Davidson N, Juozaityte E, et al. Phase III. trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer. Ann Oncol 2004; 15(10): 1527-1534. Go to original source... Go to PubMed...
    16. Batist G, Harris L, Azarnia N, et al. Improved therapeutic index of TLC D-99 (liposome-encapsulated doxorubicin) compared to free doxorubicin in first-line treatment of metastatic breast cancer in patients who had received prior adjuvant doxorubicin (abstract no. 405). Proc Am Soc Clin Oncol 2009; 19: 105a.
    17. Cardoso F, Bedard P, Winer E, et al. International Guidelines for Managment of Metastatic Breast Cancer: Combination vs Sequential Single-Agent Chemotherapy. J Natl Cancer Inst 2009; 101: 1174-1181. Go to original source... Go to PubMed...
    18. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: Phase III Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Docetaxel (ACT) with Doxorubicin and Cyclophosphamide Followed by Docetaxel and Trastuzumab (ACTH) with Docetaxel, Carboplatin and Trastuzumab (TCH) in HER2neu Positive Early Breast Cancer Patients: BCIRG 006 Study. San Antonio Breast Cancer Symposium 2009; abstract 62. Go to original source...
    19. Barlett JM, Munro A, Cameron DA, et al. Type 1 receptor tyrosine kinase profiles identify patiens with enhanced benefit from antracyclines in the BR9601 adjuvant breast cancer chemotherapy trial. J Clin Oncol 2008; 26: 5027-5035. Go to original source... Go to PubMed...
    20. Mukherjee A, Shehata M, Moseley P, et al. Topo2? protein expression predicts response to antracycline combination neo-adjuvant chemotherapy in locally advanced primary breast cancer. British Journal of Cancer 2010; 103: 1794-1800. Go to original source... Go to PubMed...
    21. Di Leo A, Desmedt J, Barlett B, et al. Final resultes of meta-analysis testing HER2 and topoisomerase II? genes as predictors of incremental benefit from anhracyclines in breast cancer. Proc Am Soc Clin Oncol 2010(72): 519. Go to original source...
    22. Seidman AD, Berry D, Cirrincione C, et al. CALGB 9840: Phase III study of weekly (W) paclitaxel (P) via 1-hour (h) infusion versus standard (S) 3h infusion every third week in the treatment of metastatic breast cancer (MBC), with trastuzumab (T) for HER2 positive MBC and randomized for T in HER2 normal MBC. J Clin Oncol 2004; 22(Suppl 512): 6. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.